25636 Federal Register / Vol. 61, No. 100 / Wednesday, May 22, 1996 / Notices

ACTION: Notice of Receipt of Notice of

Entitlement under section 2105 of the

FDA Export Reform and Enhancement

Act of 1996 (Chapter 1A of Pub. L. No.

104–134).

SUMMARY: The Patent and Trademark

Office has received notification from G.

D. Searle & Co. that it claims entitlement

under section 2105 of the FDA Export

Reform and Enhancement Act of 1996

(Chapter 1A of Pub. L. No. 104–134) for

its drug product DAYPRO—oxaprozin.

FOR FURTHER INFORMATION CONTACT:

Karin Tyson by telephone at (703) 305–

9285; by mail marked to her attention

and addressed to the Assistant

Commissioner for Patents, Box DAC,

Washington, D.C. 20231; or by fax

marked to her attention at (703) 308–

6916.

SUPPLEMENTARY INFORMATION: On April

25, 1996, the FDA Export Reform and

Enhancement Act of 1996 (Act) (Chapter

1A of Pub. L. No. 104–134) was enacted.

Section 2105 thereof grants specified

exclusive rights to the owner of the right

to market a specified nonsteroidal antiinflammatory drug who has complied

with the Act. The text of Section 2105

is as follows:

(a) In General.—Any owner on the

date of enactment of this Act of the right

to market a nonsteroidal

antiinflammatory drug that—

(1) contains a previously patented

active agent;

(2) has been reviewed by the Federal

Food and Drug Administration for a

period of more than 120 months as a

new drug application; and

(3) was approved as safe and effective

by the Federal Food and Drug

Administration on October 29, 1992,

shall be entitled, for the 2-year period

beginning on October 29, 1997, to

exclude others from making, using,

offering for sale, selling, or importing

into the United States such active agent,

in accordance with section 154(a)(1) of

title 35, United States Code.

(b) Infringement.—Section 271 of title

35, United States Code shall apply to

the infringement of the entitlement

provided under subsection (a). No

application described in section

271(e)(2)(A) of title 35, United States

Code, regardless of purpose, may be

submitted prior to the expiration of the

entitlement provided under subsection

(a).

(c) Notification.—Not later than 30

days after the date of enactment of this

Act, any owner granted an entitlement

under subsection (a) shall notify the

Commissioner of Patents and

Trademarks and the Secretary of Health

and Human Services of such

entitlement. Not later than 7 days after

receipt of such notice, the

Commissioner and Secretary shall

publish an appropriate notice of the

receipt of such notice.

On May 15, 1996, G. D. Searle & Co.,

filed a notice with the Commissioner of

Patents and Trademarks of its claim for

entitlement pursuant to Section 2105(c)

of the Act. The notice states that G. D.

Searle & Co. was the owner of the right

to market the nonsteroidal

antiinflammatory drug oxaprozin on

April 25, 1996, the date of enactment of

the Act. Further, the notice states: that

oxaprozin contains an agent that was

patented and covered by U.S. Patent No.

3,578,671; that a New Drug Application

(NDA) was filed on August 10, 1982 for

oxaprozin and was reviewed for a

period of more than 120 months; and

that oxaprozin was approved as safe and

effective by the Federal Food and Drug

Administration on October 29, 1992.

Dated: May 16, 1996.

Bruce A. Lehman,

Assistant Secretary of Commerce and

Commissioner of Patents and Trademarks.

[FR Doc. 96–12882 Filed 5–21–96; 8:45 am]

BILLING CODE 3510–16–U

COMMODITY FUTURES TRADING

COMMISSION

Chicago Mercantile Exchange

Proposed Futures and Option

Contracts on the Taiwan Stock Index

AGENCY: Commodity Futures Trading

Commission.

ACTION: Notice of availability of the

terms and conditions of proposed

commodity futures contract.

SUMMARY: The Chicago Mercantile

Exchange (CME or Exchange) has

applied for designation as a contract

market in futures and futures options on

the Taiwan Stock Index. The Acting

Director of the Division of Economic

Analysis (Division) of the Commission,

acting pursuant to the authority

delegated by Commission Regulation

140.96, has determined that publication

of the proposal for comment is in the

public interest, will assist the

Commission in considering the views of

interested persons, and is consistent

with the purposes of the Commodity

Exchange Act.

DATES: Comments must be received on

or before June 21, 1996.

ADDRESSES: Interested persons should

submit their views and comments to

Jean A. Webb, Secretary, Commodity

Futures Trading Commission, Three

Lafayette Centre, 1155 21st St., NW.,

Washington, DC 20581. Reference

should be made to the Chicago

Mercantile Exchange Taiwan Stock

Index futures and option contracts.

FOR FURTHER INFORMATION CONTACT:

Please contact Stephen Sherrod of the

Division of Economic Analysis,

Commodity Futures Trading

Commission, Three Lafayette Centre,

1155 21st St., NW., Washington, DC

20581, telephone 202–418–5277.

SUPPLEMENTARY INFORMATION: Copies of

the terms and conditions will be

available for inspection at the Office of

the Secretariat, Commodity Futures

Trading Commission, Three Lafayette

Centre, 1155 21st St., NW., Washington,

DC 20581. Copies of the terms and

conditions can be obtained through the

Office of the Secretariat by mail at the

above address or by phone at (202) 418–

5097.

Other materials submitted by the CME

in support of the application for

contract market designation may be

available upon request pursuant to the

Freedom of Information Act (5 U.S.C.

552) and the Commission’s regulations

thereunder (17 CFR Part 145 (1987)),

except to the extent they are entitled to

confidential treatment as set forth in 17

CFR 145.5 and 145.9. Requests for

copies of such materials should be made

to the FOI, Privacy and Sunshine Act

Compliance Staff of the Office of the

Secretariat at the Commission’s

headquarters in accordance with 17 CFR

145.7 and 145.8.

Any person interested in submitting

written data, views, or arguments on the

proposed terms and conditions, or with

respect to other materials submitted by

the CME, should send such comments

to Jean A. Webb, Secretary, Commodity

Futures Trading Commission, Three

Lafayette Centre, 1155 21st St., NW.,

Washington, DC 20581 by the specified

date.

Issued in Washington, DC, on May 16,

1996.

Blake Imel,

Acting Director.

[FR Doc. 96–12820 Filed 5–21–96; 8:45 am]

BILLING CODE 6351–01–P

Meetings; Sunshine Act

AGENCY HOLDING THE MEETING:

Commodity Futures Trading

Commission.

TIME AND DATE: 11:00 a.m., Friday, June

7, 1996.

PLACE: 1155 21st St. N.W., Washington,

D.C. 9th Floor Conference Room.

STATUS: Closed.

MATTERS TO BE CONSIDERED: Surveillance

Matters.